Valneva (VALN) Competitors

$5.95 +0.08 (+1.36%)

Closing price 03:58 PM Eastern

Extended Trading

$5.95 0.00 (0.00%)

As of 04:04 PM Eastern

VALN vs. AMLX, RXRX, IOVA, SNDX, and ARDX

Should you buy Valneva stock or one of its competitors? MarketBeat compares Valneva with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Valneva include Amylyx Pharmaceuticals (AMLX), Recursion Pharmaceuticals (RXRX), Iovance Biotherapeutics (IOVA), Syndax Pharmaceuticals (SNDX), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry.

How does Valneva compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Valneva (NASDAQ:VALN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Amylyx Pharmaceuticals currently has a consensus target price of $23.00, indicating a potential upside of 65.69%. Valneva has a consensus target price of $11.98, indicating a potential upside of 101.26%. Given Valneva's higher probable upside, analysts clearly believe Valneva is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Valneva's net margin of -67.64%. Amylyx Pharmaceuticals' return on equity of -55.69% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-55.69%	-50.73%
Valneva	-67.64%	-76.81%	-26.33%

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 14.9% of Valneva shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Amylyx Pharmaceuticals has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market. Comparatively, Valneva has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market.

Valneva has higher revenue and earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	17.67	-$144.74M	-$1.50	N/A
Valneva	$197.56M	2.59	-$130.33M	-$1.58	N/A

In the previous week, Amylyx Pharmaceuticals had 8 more articles in the media than Valneva. MarketBeat recorded 14 mentions for Amylyx Pharmaceuticals and 6 mentions for Valneva. Amylyx Pharmaceuticals' average media sentiment score of -0.10 beat Valneva's score of -0.15 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Amylyx Pharmaceuticals beats Valneva on 10 of the 17 factors compared between the two stocks.

How does Valneva compare to Recursion Pharmaceuticals?

Valneva (NASDAQ:VALN) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Valneva presently has a consensus target price of $11.98, suggesting a potential upside of 101.26%. Recursion Pharmaceuticals has a consensus target price of $8.10, suggesting a potential upside of 166.01%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Recursion Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Valneva has a net margin of -67.64% compared to Recursion Pharmaceuticals' net margin of -842.95%. Recursion Pharmaceuticals' return on equity of -54.33% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-67.64%	-76.81%	-26.33%
Recursion Pharmaceuticals	-842.95%	-54.33%	-40.60%

11.4% of Valneva shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valneva has a beta of 1.72, indicating that its share price is 72% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Valneva has higher revenue and earnings than Recursion Pharmaceuticals. Valneva is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.59	-$130.33M	-$1.58	N/A
Recursion Pharmaceuticals	$74.68M	21.61	-$644.76M	-$1.20	N/A

In the previous week, Recursion Pharmaceuticals had 7 more articles in the media than Valneva. MarketBeat recorded 13 mentions for Recursion Pharmaceuticals and 6 mentions for Valneva. Recursion Pharmaceuticals' average media sentiment score of 0.61 beat Valneva's score of -0.15 indicating that Recursion Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Recursion Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Recursion Pharmaceuticals beats Valneva on 8 of the 15 factors compared between the two stocks.

How does Valneva compare to Iovance Biotherapeutics?

Valneva (NASDAQ:VALN) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Valneva has higher earnings, but lower revenue than Iovance Biotherapeutics. Valneva is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.59	-$130.33M	-$1.58	N/A
Iovance Biotherapeutics	$285.61M	5.46	-$390.98M	-$0.95	N/A

In the previous week, Iovance Biotherapeutics had 12 more articles in the media than Valneva. MarketBeat recorded 18 mentions for Iovance Biotherapeutics and 6 mentions for Valneva. Iovance Biotherapeutics' average media sentiment score of 0.26 beat Valneva's score of -0.15 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.4% of Valneva shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valneva presently has a consensus target price of $11.98, suggesting a potential upside of 101.26%. Iovance Biotherapeutics has a consensus target price of $8.43, suggesting a potential upside of 141.16%. Given Iovance Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Valneva has a net margin of -67.64% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-67.64%	-76.81%	-26.33%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Valneva has a beta of 1.72, indicating that its share price is 72% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Summary

Iovance Biotherapeutics beats Valneva on 11 of the 16 factors compared between the two stocks.

How does Valneva compare to Syndax Pharmaceuticals?

Valneva (NASDAQ:VALN) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Valneva has higher earnings, but lower revenue than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.59	-$130.33M	-$1.58	N/A
Syndax Pharmaceuticals	$217.17M	8.45	-$285.42M	-$2.79	N/A

In the previous week, Valneva and Valneva both had 6 articles in the media. Syndax Pharmaceuticals' average media sentiment score of 0.05 beat Valneva's score of -0.15 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Syndax Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.4% of Valneva shares are held by institutional investors. 14.9% of Valneva shares are held by company insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valneva presently has a consensus target price of $11.98, suggesting a potential upside of 101.26%. Syndax Pharmaceuticals has a consensus target price of $42.55, suggesting a potential upside of 105.43%. Given Syndax Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Syndax Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.92

Valneva has a net margin of -67.64% compared to Syndax Pharmaceuticals' net margin of -111.88%. Valneva's return on equity of -76.81% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-67.64%	-76.81%	-26.33%
Syndax Pharmaceuticals	-111.88%	-256.65%	-45.25%

Valneva has a beta of 1.72, suggesting that its stock price is 72% more volatile than the broader market. Comparatively, Syndax Pharmaceuticals has a beta of 0.41, suggesting that its stock price is 59% less volatile than the broader market.

Summary

Valneva beats Syndax Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Valneva compare to Ardelyx?

Valneva (NASDAQ:VALN) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

In the previous week, Valneva and Valneva both had 6 articles in the media. Ardelyx's average media sentiment score of 1.05 beat Valneva's score of -0.15 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ardelyx has higher revenue and earnings than Valneva. Ardelyx is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	2.59	-$130.33M	-$1.58	N/A
Ardelyx	$427.68M	3.74	-$61.60M	-$0.23	N/A

11.4% of Valneva shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 5.3% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Valneva presently has a consensus price target of $11.98, suggesting a potential upside of 101.26%. Ardelyx has a consensus price target of $15.70, suggesting a potential upside of 142.47%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts clearly believe Ardelyx is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

Valneva has a beta of 1.72, suggesting that its share price is 72% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Ardelyx has a net margin of -13.58% compared to Valneva's net margin of -67.64%. Ardelyx's return on equity of -38.11% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-67.64%	-76.81%	-26.33%
Ardelyx	-13.58%	-38.11%	-11.85%

Summary

Ardelyx beats Valneva on 13 of the 16 factors compared between the two stocks.

Get Valneva News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VALN vs. The Competition

Export

Metric	Valneva	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$512.36M	$8.00B	$6.29B	$12.46B
Dividend Yield	N/A	2.50%	2.79%	5.30%
P/E Ratio	-3.77	18.40	20.87	25.61
Price / Sales	2.59	7.72	521.62	63.45
Price / Cash	N/A	16.76	42.94	55.34
Price / Book	4.28	3.67	9.86	6.71
Net Income	-$130.33M	$223.05M	$3.55B	$333.77M
7 Day Performance	7.01%	-1.70%	-0.26%	0.40%
1 Month Performance	-2.30%	3.65%	1.39%	4.03%
1 Year Performance	-7.18%	2.10%	41.07%	36.33%

Valneva Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VALN Valneva	2.1674 of 5 stars	$5.95 +1.4%	$11.98 +101.3%	-8.0%	$512.36M	$197.56M	N/A	700	News Coverage Earnings Report
AMLX Amylyx Pharmaceuticals	2.6506 of 5 stars	$16.38 -0.5%	$21.56 +31.6%	+224.7%	$1.82B	$87.37M	N/A	200	Trending News Earnings Report Analyst Revision
RXRX Recursion Pharmaceuticals	3.1135 of 5 stars	$3.36 -4.7%	$9.20 +174.2%	-32.4%	$1.77B	$74.68M	N/A	400	Analyst Forecast Gap Up
IOVA Iovance Biotherapeutics	2.8458 of 5 stars	$3.96 +2.8%	$8.88 +124.2%	+104.5%	$1.77B	$263.50M	N/A	500	Earnings Report Analyst Revision
SNDX Syndax Pharmaceuticals	2.9527 of 5 stars	$19.82 -0.7%	$40.50 +104.3%	+105.0%	$1.75B	$217.17M	N/A	110	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VALN) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Valneva (VALN) Competitors

VALN vs. AMLX, RXRX, IOVA, SNDX, and ARDX

How does Valneva compare to Amylyx Pharmaceuticals?

Summary

How does Valneva compare to Recursion Pharmaceuticals?

Summary

How does Valneva compare to Iovance Biotherapeutics?

Summary

How does Valneva compare to Syndax Pharmaceuticals?

Summary

How does Valneva compare to Ardelyx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN vs. The Competition

Valneva Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Valneva (VALN) Competitors

VALN vs. AMLX, RXRX, IOVA, SNDX, and ARDX

How does Valneva compare to Amylyx Pharmaceuticals?

Do analysts recommend AMLX or VALN?

Is AMLX or VALN more profitable?

Do insiders and institutionals believe in AMLX or VALN?

Which has more volatility and risk, AMLX or VALN?

Which has stronger earnings & valuation, AMLX or VALN?

Does the media refer more to AMLX or VALN?

Summary

How does Valneva compare to Recursion Pharmaceuticals?

Do analysts prefer VALN or RXRX?

Is VALN or RXRX more profitable?

Do institutionals and insiders have more ownership in VALN or RXRX?

Which has more risk & volatility, VALN or RXRX?

Which has preferable valuation & earnings, VALN or RXRX?

Does the media prefer VALN or RXRX?

Summary

How does Valneva compare to Iovance Biotherapeutics?

Which has preferable valuation & earnings, VALN or IOVA?

Does the media prefer VALN or IOVA?

Do institutionals and insiders have more ownership in VALN or IOVA?

Do analysts prefer VALN or IOVA?

Is VALN or IOVA more profitable?

Which has more risk & volatility, VALN or IOVA?

Summary

How does Valneva compare to Syndax Pharmaceuticals?

Which has higher valuation and earnings, VALN or SNDX?

Does the media favor VALN or SNDX?

Do insiders & institutionals have more ownership in VALN or SNDX?

Do analysts rate VALN or SNDX?

Is VALN or SNDX more profitable?

Which has more risk and volatility, VALN or SNDX?

Summary

How does Valneva compare to Ardelyx?

Does the media favor VALN or ARDX?

Which has stronger earnings and valuation, VALN or ARDX?

Do institutionals & insiders have more ownership in VALN or ARDX?

Do analysts rate VALN or ARDX?

Which has more volatility & risk, VALN or ARDX?

Is VALN or ARDX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VALN vs. The Competition

Valneva Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools